Explore

TrendlineTrendline
Non-Surgical Anti-Aging Treatments Offer Structural Improvements with Minimal Downtime

Non-Surgical Anti-Aging Treatments Offer Structural Improvements with Minimal Downtime

Non-Surgical Anti-Aging Treatments Offer Structural Improvements with Minimal Downtime
Rapid ReadRapid Read
HHS Launches SURPASS Program to Revolutionize Clinical Trial Design with AI

HHS Launches SURPASS Program to Revolutionize Clinical Trial Design with AI

The U.S. Department of Health and Human Services (HHS) has initiated the SURPASS program, an AI-driven effort aimed at transforming clinical trial design and execution. This five-year program, operated by the Advanced Research Projects Agency for Health (ARPA-H), seeks to move beyond traditional fixed-phase trials by integrating predictive computational models, continuous analysis, and automated operations. SURPASS, which stands for Simulation-augmented, Real-time Platform Adaptive Seamless Trials, is designed to identify hidden protocol risks, such as overly restrictive eligibility criteria and patient dropout patterns, through AI-driven simulations. The initiative combines adaptive platform trial design, AI-enabled site activation, a nationwide data infrastructure, and patient data contribution tools. This comprehensive approach is intended to reduce trial timelines, costs, and patient burden, ultimately speeding up the development of new drugs and therapies. The program is part of a larger federal initi...
Discover dailyDiscover daily
The FDA Got Its Familiar Name in 1930

The FDA Got Its Familiar Name in 1930

The Food and Drug Administration (FDA) stands as a pivotal federal agency within the United States Department of Health and Human Services, tasked ...
TrendlineTrendline
Greenberg Traurig Bolsters Health Care FDA Practice with Gail Javitt in Washington, D.C.

Greenberg Traurig Bolsters Health Care FDA Practice with Gail Javitt in Washington, D.C.

Greenberg Traurig Bolsters Health Care FDA Practice with Gail Javitt in Washington, D.C.
Rapid ReadRapid Read
FDA and Health Canada Warn Against Combining Methylene Blue with Antidepressants Due to Serotonin Syndrome Risk

FDA and Health Canada Warn Against Combining Methylene Blue with Antidepressants Due to Serotonin Syndrome Risk

Health Canada and the U.S. FDA issued warnings in 2011 regarding the significant risk of serotonin syndrome when methylene blue is combined with certain antidepressants. Methylene blue is identified as a potent MAO-A inhibitor, an action similar to older MAOI antidepressants. When taken with antidepressants, particularly SSRIs, which increase serotonin levels in the brain, methylene blue prevents the body from breaking down this excess serotonin. This can lead to a dangerous accumulation of serotonin, resulting in serotonin syndrome. The Mayo Clinic indicates that symptoms of serotonin syndrome typically appear within hours of starting a new drug or increasing a dose, and can include restlessness, confusion, a racing heart, heavy sweating, shivering, goosebumps, muscle twitching, and diarrhea. Severe cases can involve high fever, seizures, irregular heartbeat, loss of consciousness, and can be fatal. The warnings highlight that even doses below typical hospital ranges can meaningfully block the enzyme resp...
USA TodayUSA Today
NAD IV therapy promises more energy. But it could come at a cost

NAD IV therapy promises more energy. But it could come at a cost

Sometimes, even an essential nutrient can be repackaged to seem more transformative than the science suggests. NAD IV therapy is a prime example.
Rapid ReadRapid Read
Democratic Women's Caucus Urges HHS and FDA to Address Estradiol Patch Shortage

Democratic Women's Caucus Urges HHS and FDA to Address Estradiol Patch Shortage

The Democratic Women's Caucus (DWC), led by Senate Liaison and Caregiving Task Force Co-Chair Debbie Dingell (MI-06), DWC Member Val Hoyle (OR-04), DWC Reproductive Task Force Co-Chair and Liaison Ayanna Pressley (MA-07), and DWC Member Yvette D. Clarke (NY-09), has sent a letter to the Food and Drug Administration's (FDA) Acting Commissioner Kyle Diamantas and Health & Human Services Secretary Robert F. Kennedy Jr. (RFK Jr.). The letter, signed by 44 DWC members including Laura Friedman, demands immediate action to resolve the ongoing shortage of estradiol transdermal patches, also known as estrogen patches. These patches are crucial for managing menopause symptoms and protecting women's long-term bone and cardiovascular health. The DWC highlighted that prescriptions for estrogen patches have increased by 162% over the past two years, partly due to the removal of a black box warning label. This surge in demand, coupled with a lack of manufacturing capacity and perceived inaction from the FDA, has left mil...
Rapid ReadRapid Read
NAD IV Therapy Lacks Scientific Evidence for Health Benefits, Poses Risks and High Costs

NAD IV Therapy Lacks Scientific Evidence for Health Benefits, Poses Risks and High Costs

NAD IV therapy, promoted on social media for increased energy, sharper focus, and anti-aging, lacks strong scientific evidence to support its claimed health benefits, according to Dr. Zachary Mulvihill, an integrative health and well-being physician at NewYork-Presbyterian and Weill Cornell Medicine. While nicotinamide adenine dinucleotide (NAD) is an essential molecule derived from vitamin B3, crucial for over 400 enzyme reactions and cellular energy, its intravenous administration is not approved by the U.S. Food and Drug Administration (FDA) for any medical condition. Animal studies suggesting NAD's role in metabolic health and age-related cellular function have not been replicated in humans, and much of that research focused on NAD precursors, not IV infusions. Treatments can cost hundreds of dollars per session, are rarely covered by insurance, and carry substantial side effects, including abdominal cramping, nausea, increased heart rate, and chest pressure. Concerns also exist regarding product quali...
TrendlineTrendline
Non-Surgical Body Sculpting Technologies Advance for Targeted Body Contouring

Non-Surgical Body Sculpting Technologies Advance for Targeted Body Contouring

Non-Surgical Body Sculpting Technologies Advance for Targeted Body Contouring
Rapid ReadRapid Read
Senator Hawley Calls for National Ban on Abortion Drug Mifepristone, Citing Safety Concerns and Increased Abortions

Senator Hawley Calls for National Ban on Abortion Drug Mifepristone, Citing Safety Concerns and Increased Abortions

U.S. Sen. Josh Hawley (R-Mo.) is advocating for a national ban on the abortion drug mifepristone, asserting that it is unsafe for both the unborn and the mother. He has introduced the Safeguarding Women from Chemical Abortion Act, which aims to revoke the FDA's approval of the drug. According to Senator Hawley, mifepristone is responsible for a significant increase in abortions, with more abortions occurring now than when Roe v. Wade was in effect. He claims that the drug leads to hospitalization for 11% of expectant mothers who use it, citing life-threatening conditions such as hemorrhaging, infections, and sepsis. Senator Hawley argues that pharmaceutical companies profit from the increased number of abortions facilitated by the drug. He also stated that the drug has turned 'every mailbox in America into a Planned Parenthood clinic,' making it accessible regardless of local regulations. The legislation has garnered seven Senate co-sponsors.
Rapid ReadRapid Read
Tempus AI Receives FDA Clearance for AI Tool to Detect Mitral Regurgitation from ECGs

Tempus AI Receives FDA Clearance for AI Tool to Detect Mitral Regurgitation from ECGs

Tempus AI has secured U.S. FDA 510(k) clearance for its new artificial intelligence tool, Tempus ECG-MR. This software is designed to identify indicators of previously undiagnosed moderate or severe mitral regurgitation using standard 12-lead electrocardiograms (ECGs). The tool provides a binary result, signaling whether an ECG contains patterns associated with the condition. It is specifically intended for patients aged 65 and older who have cardiovascular risk factors or symptoms suggestive of heart disease. The AI analyzes resting, non-ambulatory ECGs collected in healthcare facilities, looking for specific patterns linked to mitral regurgitation, a condition where the heart's mitral valve fails to close properly, leading to backward blood flow. This clearance marks Tempus AI's fourth FDA-cleared ECG-AI product, expanding its cardiovascular diagnostic portfolio.
Rapid ReadRapid Read
Origin Genomics Challenges U.S. Ban on Gene-Edited Embryos for Disease Prevention

Origin Genomics Challenges U.S. Ban on Gene-Edited Embryos for Disease Prevention

Origin Genomics, a U.S. startup led by CEO Cathy Tie, is actively working to advance gene-editing technology for human embryos, aiming to prevent severe genetic diseases. This effort directly challenges the current U.S. law that prohibits the use of gene-edited human embryos to create babies due to ethical and safety concerns. The company is conducting research to demonstrate the safety and efficacy of newer, more precise gene-editing techniques, such as prime editing and base editing. Origin Genomics extracts stem cells from donated embryos, which come from couples affected by life-threatening genetic disorders, to test molecular tools designed to correct genetic defects. The goal is to prevent these diseases from being passed down to future generations. Nicole and Asaf Ezra, a couple struggling with familial adenomatous polyposis, have invested in Origin and donated embryos for research, highlighting the personal stakes involved in this controversial field.